HKMPF (Pharmaceuticals) Stock Valuation & Fair Value Fairly valued
HKMPF (Pharmaceuticals) trades at a blended P/E of 9.6, about 44% below its historical normal valuation, with a forward growth estimate of 7.2% and a PEG of 1.33. Analysts' one-year estimates have been hit 36% of the time.
No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.
Valuation flags
- No notable valuation flags.
Verdict history
tickerseer's rating has been fairly valued since 2026-09-19.
Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.
Frequently asked questions
Is HKMPF overvalued?
At a blended P/E of 9.6 versus its historical normal P/E of 17.3, HKMPF trades about 44% below its typical valuation, with a PEG of 1.33 on 7.2% forward growth. tickerseer currently rates it fairly valued.
What is HKMPF's fair value and PEG?
HKMPF trades at a blended P/E of 9.6 against a historical normal P/E of 17.3, a PEG of 1.33, and a forward growth estimate of 7.2%.
Has tickerseer's rating of HKMPF changed?
tickerseer's rating has been fairly valued since 2026-09-19.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.